Prevention of EAE by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
March 9th, 2011 by kathibbetson
This study examined the long term effects of the opioid growth factor (OGF, [Met(5)]-enkephalin) and a low dose of the opioid blocker naltrexone (LDN) on induced EAE
Tags: 
